4H-1,3-Benzothiazin-4-one, 8-nitro-6-(trifluoromethyl)-2-[4-[[4-(trifluoromethyl)-1-piperidinyl]methyl]-1-piperidinyl]-

Tuberculosis inhibitor 3 (compound 2i) displays potent anti-TB activity (MIC < 0.016 μg/mL) against drug-sensitive/resistant MTB strains. Tuberculosis inhibitor 3 (compound 2i) shows acceptable PK profiles with oral bioavailability[1]. Tuberculosis inhibitor 3 (compound 2i, 50 mg/kg) shows acceptable PK properties with the AUC of 2489 h?ng/mL) is. The Tmax of Tuberculosis inhibitor 3 is 0.25 h[1].

[1]. Kai Lv, et al. Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety. Eur J Med Chem. 2018 May 10;151:1-8.